Alla V. Kulakova

Alla V. Kulakova

Auto-generated profile, based on publicly available information

Alla V. Kulakova

Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Toxicology Letters
Verified
Journal Article
Closed access
AZAliy K. Zhanataev
Aliy K. Zhanataev
EAElena A. Anisina
Elena A. Anisina
AKAlla V. Kulakova
Alla V. Kulakova
ISIgor Shilovskiy
Igor Shilovskiy
ALArtem A. Lisitsyn
Artem A. Lisitsyn
ADAndrey D. Durnev
Andrey D. Durnev

30 December 2025 in Ecological genetics
Verified
Journal Article
Open access
AZAliy K. Zhanataev
Aliy K. Zhanataev
EAElena A. Anisina
Elena A. Anisina
AKAlla V. Kulakova
Alla V. Kulakova
ADAndrey D. Durnev
Andrey D. Durnev
BACKGROUND: Experimental data on tissue-specific effects and antigenotoxic potential facilitate more targeted practical applications of antigenotoxicants. AIM: This work aimed to assess the tissue-specific antigenotoxic activity of the natural flavonoids apigenin, naringenin, and hesperetin against the DNA-damaging effects of temozolomide and the cytogenetic effects of genotoxicants with various mechanisms of action. METHODS: The genotoxicants (temozolomide 50 mg/kg, cyclophosphamide 20 mg/kg, methyl methanesulfonate 80 mg/kg, and dioxydin 250 mg/kg) were administered intraperitoneally to mice. Before genotoxicant injections, three oral doses of apigenin (5, 25, and 50 mg/kg) and naringenin and hesperetin (25, 50, and 100 mg/kg) were given. In a separate experiment, apigenin was administered one hour after temozolomide injection. The study used a comet assay in bone marrow, liver, kidney, brain, and rectum cells, as well as chromosome aberration analysis in bone marrow cells. RESULTS: Apigenin decreased temozolomide-induced DNA damage in the bone marrow (52%–66%), liver (31%–65%), kidneys (50%), and rectum (100%), but not in the brain. All apigenin doses reduced kidney levels of atypical DNA comets. Naringenin demonstrated antigenotoxic activity by reducing DNA damage in the bone marrow (48%–62%), brain (26%–44%), and rectum (49%–54%), but not in the liver or kidneys. Hesperetin showed antigenotoxic effects in the bone marrow (23%), kidneys (29%–33%), brain (23%–42%), and rectum (32%–47%). In a cytogenetic assay, apigenin, naringenin, and hesperetin dose-dependently reduced the effects of temozolomide by 49%–73%, 49%–75%, and 39%–55%, respectively. In the post-treatment mode, apigenin 5–50 mg/kg reduced the effects of temozolomide by 47%–51%. Apigenin 5 mg/kg and 25 mg/kg markedly reduced the cytogenetic effects of dioxydin, while apigenin 25 mg/kg decreased those of cyclophosphamide and methyl methanesulfonate. Naringenin 50 mg/kg and 100 mg/kg reduced the effect of cyclophosphamide (43%–71%), but not dioxydin. CONCLUSION: Apigenin, naringenin, and hesperetin show tissue-specific antigenotoxic activity against the effects of temozolomide. Apigenin and naringenin reduce the cytogenetic effects of genotoxicants with various mechanisms of damaging action. The findings highlight the potential of the investigated flavonoids as genome-protecting agents with a possible targeted action.

12 May 2023 in Ecological genetics
Verified
Journal Article
Open access
PDF file
AZAliy K. Zhanataev
Aliy K. Zhanataev
AKAlla V. Kulakova
Alla V. Kulakova
ADAndrey D. Durnev
Andrey D. Durnev
BACKGROUND: The causal relationship between mutagenesis and carcinogenesis is well known. Hence the wide interest in the study of the mutagen-modifying effects of natural and synthetic compounds. Particular attention is drawn to widespread compounds. One of them, metformin, is widely used as a hypoglycemic drug. AIM: evaluation of the influence of metformin on the cytogenetic effects of doxorubicin and cyclophosphamide in mouse bone marrow cells. MATERIALS AND METHODS: Male F1 CBAxC57Bl/6 hybrid mice were used. Cyclophosphamide (20 mg/kg) or doxorubicin (10 mg/kg) was administered intraperitoneally, metformin was given orally once or for 4 consecutive days. The latter administration of metformin was combined with mutagen administration. Cytogenetic preparations of bone marrow cells were prepared 18 hours after metformin administration and 24 hours after its combined administration with mutagens. Chromosomal aberrations were analyzed according to accepted protocols. RESULTS: Metformin per se showed no cytogenetic activity at doses of 500, 1000, and 2000 mg/kg. At a dose of 500 mg/kg, but not 100 or 250 mg/kg, metformin reduced the cytogenetic effects of doxorubicin. Metformin administered once and for 4 days at doses of 100, 250, and 500 mg/kg or once at doses of 10 and 20 mg/kg increased the number of metaphases with chromosome aberrations induced by cyclophosphamide by a factor of 2 to 3. At doses of 2.5 and 5 mg/kg, metformin had no modifying effect on the mutagen effect. CONCLUSION: Metformin attenuates the cytogenetic effects of doxorubicin and enhances the cytogenetic activity of cyclophosphamide in mouse bone marrow cells. This allows us to conclude that metformin has mutagen-modifying properties.

19 June 2020 in Известия вузов. Пищевая технология
Verified
Journal Article
Closed access
ЕВЕ.а. Вербицкая
Е.а. Вербицкая
АКА.в. Кулакова
А.в. Кулакова
ВИВ.в. Илларионова
В.в. Илларионова
АДА.н. Дроздов
А.н. Дроздов
МФМ.в. Филенкова
М.в. Филенкова
СКС.а. Калманович
С.а. Калманович